Keyphrases
Phase II Study
100%
Docetaxel
60%
Overall Survival
59%
Phase II Trial
54%
Gemcitabine
53%
Progression-free Survival
48%
Bevacizumab
42%
Sunitinib
39%
Phase I Study
38%
Chemotherapy
34%
Tumor
34%
Prostate Cancer
33%
Partial Response
31%
Metastatic Renal Cell Carcinoma (mRCC)
29%
Hormone-sensitive Prostate Cancer
29%
Metastatic Urothelial Carcinoma
28%
Confidence Interval
28%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
27%
Prostate-specific Antigen
26%
Oncology
25%
Androgen Deprivation Therapy
23%
Radiation Therapy
23%
Previously Treated
22%
Colorectal Cancer
21%
Cisplatin
21%
Stable Disease
21%
Metastatic Colorectal Cancer (mCRC)
20%
Leukemia
20%
Erlotinib
20%
Castration-resistant Prostate Cancer
19%
Maximum Tolerated Dose
18%
Tumor Response
18%
Intermediate Risk
17%
Everolimus
17%
Poor Risk
17%
Monotherapy
17%
Resectable Pancreatic Cancer
17%
Median Progression-free Survival
16%
CABOSUN
16%
Cabozantinib
16%
Prostate Cancer Patients
16%
Objective Response Rate
16%
Metastatic Urothelial Cancer
15%
5-fluorouracil (5-FU)
15%
Dose Level
15%
Chemoradiation
15%
Placebo
15%
Metastatic Disease
15%
Pancreatic Cancer
14%
Irinotecan
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
78%
Malignant Neoplasm
65%
Diseases
64%
Docetaxel
58%
Overall Survival
52%
Gemcitabine
49%
Neoplasm
49%
Progression Free Survival
47%
Bevacizumab
42%
Chemotherapy
42%
Solid Malignant Neoplasm
35%
Androgen
32%
Transitional Cell Carcinoma
30%
Sunitinib
30%
Renal Cell Carcinoma
29%
Pancreas Cancer
27%
Castration Resistant Prostate Cancer
25%
Phase II Trials
25%
Adverse Event
24%
Prostate Specific Antigen
24%
Chemoradiation Therapy
23%
Cisplatin
22%
Kidney Metastasis
21%
Pharmacokinetics
20%
Erlotinib
20%
Monotherapy
17%
Placebo
16%
Doxorubicin
16%
Metastatic Colorectal Cancer
16%
Leukemia
16%
Maximum Tolerated Dose
16%
Pharmacodynamics
15%
Protein Tyrosine Kinase Inhibitor
15%
Colorectal Carcinoma
13%
Pancreas Adenocarcinoma
13%
Bile Duct Cancer
13%
Irinotecan
12%
Antitumor Activity
12%
Epidermal Growth Factor Receptor
12%
Cabozantinib
12%
Temsirolimus
12%
Capecitabine
12%
Gastrointestinal Stromal Tumor
12%
Everolimus
12%
Protein Tyrosine Kinase
12%
Neutropenia
11%
Androgen Receptor
10%
Imatinib
10%
Adenocarcinoma
10%
Vasculotropin
9%
Medicine and Dentistry
Prostate Cancer
53%
Neoplasm
46%
Overall Survival
45%
Gemcitabine
41%
Diseases
38%
Progression Free Survival
38%
Radiation Therapy
35%
Malignant Neoplasm
34%
Transitional Cell Carcinoma
33%
Sunitinib
27%
Bevacizumab
25%
Chemoradiotherapy
25%
Cisplatin
23%
Docetaxel
22%
Pancreas Cancer
20%
Oncology
20%
Phase II Trials
19%
Clear Cell Renal Cell Carcinoma
19%
Rectum Cancer
18%
Kidney Metastasis
17%
Solid Malignant Neoplasm
17%
Urothelial Cancer
17%
Rectum Carcinoma
17%
Cabozantinib
16%
Placebo
16%
Leukemia
16%
Preoperative Radiotherapy
16%
Preoperative Treatment
14%
Androgen Receptor
13%
Androgen
13%
Metastatic Carcinoma
12%
Positron Emission Tomography
12%
Metastatic Colorectal Cancer
12%
Erlotinib
12%
Cancer
12%
Fluorouracil
12%
Prostate Specific Antigen
11%
Tyrosine-Kinase Inhibitor
11%
Surgery
11%
Local Therapy
11%
Neuroendocrine Tumor
10%
Adverse Event
10%
Protein Tyrosine Kinase
10%
Arm
10%
Androgen Deprivation Therapy
10%
Germinoma
9%
Recurrent Disease
9%
Everolimus
9%
Antineoplastic Activity
9%
Targeted Therapy
9%